Key facts for Q5115
- Billing unit
- 10 MG
- Inj truxima 10 mg
- ASP payment limit
- $35.988
- October 2026; +4.1% vs July 2026
- Practitioner MUE
- 150
- MAI 3
- NCCI exposure
- no PTP pairs
- Coverage articles
- 4
- 15 states
TL;DR
HCPCS Q5115 is the Level II code for Injection, rituximab-abbs, biosimilar, (truxima), 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $35.988 per billing unit, up 4.1% from July 2026. The practitioner MUE allows up to 150 units per date of service (MAI 3), so a full 150-unit day is $5,398.20 at the current limit. Under OPPS it carries status indicator K in APC 9336. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. Other HCPCS codes whose descriptor names rituximab: Q5119 (biosimilar rituximab-pvvr (Ruxience) from Pfizer Inc); Q5123 (biosimilar rituximab-arrx (Riabni) from Amgen Inc); J9312 (non-biosimilar rituximab (Rituxan) from Genentech, Inc). The ASP crosswalk maps 2 NDCs to it, sold as Truxima by Cephalon, LLC. 4 Medicare coverage articles list the code across 15 states, including A55639.
Medicare Part B payment limit (ASP)
CMS sets the Part B payment limit for Q5115 at $35.988 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $34.563 in July 2026. Beneficiary coinsurance is 20%.
| Quarter | Payment limit | Per | Coinsurance |
|---|---|---|---|
| October 2026 | $35.988 | 10 MG | 20% |
| July 2026 | $34.563 | 10 MG | — |
NDC to HCPCS billing-unit conversion
The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to Q5115. Report the NDC in the claim's drug segment and bill the number of Q5115 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.
| NDC | Drug name | Labeler | Package size | Billing units / package |
|---|---|---|---|---|
| 63459-0103-10 | Truxima | Cephalon, LLC | 10 × 1 | 10 |
| 63459-0104-50 | Truxima | Cephalon, LLC | 50 × 1 | 50 |
Medically Unlikely Edits (MUE)
CMS publishes 2 MUE values for Q5115. For practitioners the limit is 150 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.
| Setting | MUE (units/DOS) | MAI | CMS rationale |
|---|---|---|---|
| Practitioner services | 150 | 3 Date of Service Edit: Clinical | Prescribing Information |
| Facility outpatient hospital | 150 | 3 Date of Service Edit: Clinical | Prescribing Information |
MUE for Q5115 in every setting opens the lookup with this code filled in, next to any other code on the same claim.
NCCI edits and add-on relationships
No active practitioner PTP pair lists Q5115 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.
The counts above are exposure, not answers for a specific claim. Check Q5115 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.
Q5115 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.
Medicare coverage articles
4 current Medicare Administrative Contractor articles list Q5115 in their HCPCS tables, covering 15 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.
| Article | Title | Contractor(s) | States | Related LCD |
|---|---|---|---|---|
| A55639 | Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions | Wisconsin Physicians Service Insurance Corporation | IA KS MO NE | L37205 |
| A56380 | Billing and Coding: Rituximab | Palmetto GBA | NC SC VA WV | L35026 |
| A58582 | Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars | CGS Administrators, LLC | KY OH | L38920 |
| A59101 | Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars | Wellpoint Federal | CT IL MN NY WI | L39297 |
Diagnoses Medicare contractors cover for Q5115
4 billing and coding articles attach a covered diagnosis list to Q5115: 945 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).
| ICD-10-CM | Description (FY2027) | Articles covering |
|---|---|---|
| D59.0 | Drug-induced autoimmune hemolytic anemia | 4 of 4 |
| D59.11 | Warm autoimmune hemolytic anemia | 4 of 4 |
| D59.12 | Cold autoimmune hemolytic anemia | 4 of 4 |
| D59.13 | Mixed type autoimmune hemolytic anemia | 4 of 4 |
| D69.3 | Immune thrombocytopenic purpura | 4 of 4 |
| D69.41 | Evans syndrome | 4 of 4 |
| G35.A | Relapsing-remitting multiple sclerosis | 4 of 4 |
| G36.0 | Neuromyelitis optica [Devic] | 4 of 4 |
| G70.00 | Myasthenia gravis without (acute) exacerbation | 4 of 4 |
| G70.01 | Myasthenia gravis with (acute) exacerbation | 4 of 4 |
| L12.0 | Bullous pemphigoid | 4 of 4 |
| M33.12 | Other dermatomyositis with myopathy | 4 of 4 |
| M33.22 | Polymyositis with myopathy | 4 of 4 |
| N04.0 | Nephrotic syndrome with minor glomerular abnormality | 4 of 4 |
| M31.11 | Hematopoietic stem cell transplantation-associated thrombotic microangiopathy [HSCT-TMA] | 4 of 4 |
Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5115 are counted here: a group whose instructions name Q5115, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.
| Article | Contractor | Groups that apply | Covered codes for Q5115 | Full list |
|---|---|---|---|---|
| A55639 | Wisconsin Physicians Service Insurance Corporation | 6 groups apply to Q5115 | 309 | On LCD L37205 |
| A56380 | Palmetto GBA | groups 1 and 2 apply to Q5115 | 692 | On LCD L35026 |
| A58582 | CGS Administrators, LLC | one list for every code in the article | 49 | On LCD L38920 |
| A59101 | Wellpoint Federal | one list for every code in the article | 836 | On LCD L39297 |
Local coverage policies that list Q5115
4 active Local Coverage Determinations list Q5115 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.
- Rituximab (L35026) · Palmetto GBA
- LCD L39297: Off-label Use of Rituximab and Rituximab Biosimilars · Wellpoint Federal
- L37205 Chemotherapy Drugs and their Adjuncts · Wisconsin Physicians Service Insurance Corporation
- L38920 Off-label Use of Rituximab and Rituximab Biosimilars · CGS Administrators, LLC
Hospital outpatient (OPPS) status
In the October 2026 OPPS Addendum B, Q5115 carries status indicator K and is assigned to APC 9336, with a published national unadjusted payment of $35.988. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.
Ambulatory surgical center (ASC) payment
In the October 2026 ASC Addendum BB (covered ancillary services), Q5115 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $35.99 per 10 MG, paid only when the drug is furnished integral to a covered surgical procedure.
Common denials for Q5115 and how to prevent them
For teams evaluating QuickIntell software
Evaluate a coding workflow for Q5115
Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
In QuickIntell research
- J codes by drug name: Every code for the same drug, generic or brand, in one A-Z index.
Frequently asked questions — HCPCS Q5115
What does HCPCS code Q5115 describe?
Q5115 is defined by CMS as "Injection, rituximab-abbs, biosimilar, (truxima), 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.
Is Q5115 a CPT code?
No. Q5115 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as rituximab-abbs (Truxima); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5115 reports the drug itself in 10 mg units, and the administration is billed on its own line.
What is the Medicare reimbursement for Q5115 in October 2026?
The ASP-based payment limit is $35.988 per 10 MG, with 20% beneficiary coinsurance. The July 2026 limit was $34.563. Commercial payers use their own fee schedules.
How many units of Q5115 can be billed per day?
The practitioner Medically Unlikely Edit is 150 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.
Which NDCs map to Q5115?
The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Truxima (Cephalon, LLC). For example NDC 63459-0103-10 (package size 10) equals 10 billing units of Q5115.
Does Q5115 have NCCI bundling edits?
No active practitioner PTP pairs list Q5115 as a column-1 or column-2 code in the v323r0 release.
Q5115 vs Q5119: what is the difference?
Both are HCPCS Level II codes whose descriptor names rituximab. What sets Q5119 apart: biosimilar rituximab-pvvr (Ruxience) from Pfizer Inc. Q5115 is billed per 10 mg, limit $35.988, MUE 150; Q5119 is billed per 10 mg, limit $5.792, MUE 150. Report the code whose descriptor matches the product and setting in the record.
Q5115 vs Q5123: what is the difference?
Both are HCPCS Level II codes whose descriptor names rituximab. What sets Q5123 apart: biosimilar rituximab-arrx (Riabni) from Amgen Inc. Q5115 is billed per 10 mg, limit $35.988, MUE 150; Q5123 is billed per 10 mg, limit $21.083, MUE 150. Report the code whose descriptor matches the product and setting in the record.
Which Medicare coverage articles mention Q5115?
4 current Billing and Coding Articles in the Medicare Coverage Database list Q5115, covering 15 states: A55639 (Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions); A56380 (Billing and Coding: Rituximab); A58582 (Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars).
What diagnosis codes support Q5115?
4 Medicare billing and coding articles list 945 covered ICD-10-CM codes for Q5115 between them, for example D59.0 (Drug-induced autoimmune hemolytic anemia); D59.11 (Warm autoimmune hemolytic anemia); D59.12 (Cold autoimmune hemolytic anemia); D59.13 (Mixed type autoimmune hemolytic anemia); D69.3 (Immune thrombocytopenic purpura). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- Medicare Part B Drug Payment Limit File, July 2026Version July 2026 · effective 2026-07-01 · file section 508 version of July 2026 Medicare Part B Payment Limit File updated 082026.csvSHA-256 13bb5b644b92b574…
- ASP NDC-HCPCS Crosswalk, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 ASP NDC-HCPCS Crosswalk 091126.csvSHA-256 5cb78f0c2ee786ba…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI MUE table, facility services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_OutpatientHospitalServices_Eff_10-01-2026.csvSHA-256 3af9f4e99cc587e2…
- NCCI MUE table, dme services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_DMESupplierServices_Eff_10-01-2026.csvSHA-256 6fa4fbba852f7b74…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- NCCI Add-On Code edits, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file AOC_V2026Q4-F-MCR.xlsxSHA-256 eabb519623134549…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
- ASC Addendum BB (covered ancillary services), October 2026Version October 2026 · effective 2026-10-01 · file Oct 2026 ASC BB.txtSHA-256 63cdd7c72aba7a25…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.